These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination. Leier CB; Magorien RD; Desch CE; Thompson MJ; Unverferth DV Circulation; 1981 Jan; 63(1):102-9. PubMed ID: 7438384 [TBL] [Abstract][Full Text] [Related]
43. Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. Packer M; Meller J; Medina N; Yushak M; Gorlin R N Engl J Med; 1982 Jan; 306(2):57-62. PubMed ID: 7053487 [TBL] [Abstract][Full Text] [Related]
44. Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure. Leier CV; Bambach D; Thompson MJ; Cattaneo SM; Goldberg RJ; Unverferth DV Am J Cardiol; 1981 Dec; 48(6):1115-23. PubMed ID: 6795915 [No Abstract] [Full Text] [Related]
45. Comparative hemodynamic effects of intravenous nitroprusside and oral prazosin in refractory heart failure. Mehta J; Iacona M; Feldman RL; Pepine CJ; Conti CR Am J Cardiol; 1978 May; 41(5):925-30. PubMed ID: 645603 [No Abstract] [Full Text] [Related]
46. Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure. Artman M; Parrish MD; Appleton S; Boucek RJ; Graham TP Am Heart J; 1987 Jan; 113(1):144-50. PubMed ID: 3799428 [TBL] [Abstract][Full Text] [Related]
47. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy. Packer M; Meller J; Medina N; Yushak M; Gorlin R Am J Cardiol; 1981 Nov; 48(5):939-46. PubMed ID: 7304442 [TBL] [Abstract][Full Text] [Related]
48. Specific afterload reduction with parenteral hydralazine following cardiac surgery. Sladen RN; Rosenthal MH J Thorac Cardiovasc Surg; 1979 Aug; 78(2):195-202. PubMed ID: 459526 [TBL] [Abstract][Full Text] [Related]
49. Oral hydralazine therapy for chronic refractory heart failure. Chatterjee K; Parmley WW; Massie B; Greenberg B; Werner J; Klausner S; Norman A Circulation; 1976 Dec; 54(6):879-83. PubMed ID: 825327 [TBL] [Abstract][Full Text] [Related]
50. Treatment of canine low pressure pulmonary edema. Nitroprusside versus hydralazine. Harrison WD; Raizen M; Ghignone M; Girling L; Slykerman LJ; Prewitt RM Am Rev Respir Dis; 1983 Nov; 128(5):857-61. PubMed ID: 6638674 [TBL] [Abstract][Full Text] [Related]
51. Effects of hydralazine and nitroprusside on cardiopulmonary function when a decrease in cardiac output complicates a short-term increase in pulmonary vascular resistance. Lee KY; Molloy DW; Slykerman L; Prewitt RM Circulation; 1983 Dec; 68(6):1299-303. PubMed ID: 6640879 [TBL] [Abstract][Full Text] [Related]
52. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Shekhar YC; Anand IS; Sarma R; Ferrari R; Wahi PL; Poole-Wilson PA Am J Cardiol; 1991 Apr; 67(8):732-6. PubMed ID: 2006623 [TBL] [Abstract][Full Text] [Related]
53. Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure. Haitas B; Meyer TE; Angel ME; Reef E Br J Clin Pharmacol; 1990 Mar; 29(3):366-8. PubMed ID: 2310661 [TBL] [Abstract][Full Text] [Related]
54. Hypotension and arteriovenous shunting: effects of intravenous infusion of nitroprusside, nitroglycerin and phentolamine. Dumont L; Lamoureux C; Lelorier J; Stanley P; Chartrand C Angiology; 1984 Feb; 35(2):88-96. PubMed ID: 6421204 [TBL] [Abstract][Full Text] [Related]
55. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. Elkayam U; Roth A; Hsueh W; Weber L; Freidenberger L; Rahimtoola SH Am Heart J; 1986 Jun; 111(6):1130-8. PubMed ID: 2872793 [TBL] [Abstract][Full Text] [Related]
56. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Ljungman S; Laragh JH; Cody RJ Drugs; 1990; 39 Suppl 4():10-21; discussion 22-4. PubMed ID: 2354670 [TBL] [Abstract][Full Text] [Related]
57. Effects of hydralazine on coronary blood flow and myocardial energetics in congestive heart failure. Magorien RD; Brown GP; Unverferth DV; Nelson S; Boudoulas H; Bambach D; Leier CV Circulation; 1982 Mar; 65(3):528-33. PubMed ID: 7055874 [TBL] [Abstract][Full Text] [Related]
58. Sodium nitroprusside therapy in congestive cardiomyopathy-variability in hemodynamic response. Mookherjee S; Henion W; Warner R; Eich RH; Smulyan H; Obeid AI J Clin Pharmacol; 1978 Jan; 18(1):67-75. PubMed ID: 338648 [TBL] [Abstract][Full Text] [Related]
59. Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction. Miller RR; Awan NA; Joye JA; Maxwell KS; DeMaria AN; Amsterdam EA; Mason DT Circulation; 1977 Jun; 55(6):881-4. PubMed ID: 858184 [TBL] [Abstract][Full Text] [Related]
60. Comparative effects on hemodynamics of enoximone (MDL 17,043), dobutamine and nitroprusside in severe congestive heart failure. Installé E; Gonzalez M; Jacquemart JL; Collard P; Roulette F; Pourbaix S; Tremouroux J Am J Cardiol; 1987 Aug; 60(5):46C-52C. PubMed ID: 2956868 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]